MYCN and neuroblastoma: Based on these findings, PET imaging may be further studied as a biomarker that identifies patients with NB or other cancers who would most likely to benefit from novel therapies targeting MYC/MYCN [28, 36] or the glycolytic pathway [34, 35, 37].